Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
24 hedge funds and large institutions have $1.93M invested in Oncternal Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 14 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
30% less capital invested
Capital invested by funds: $2.74M → $1.93M (-$812K)
31% less funds holding
Funds holding: 35 → 24 (-11)
79% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Aureus Asset Management
Boston,
Massachusetts
|
+$542K |
| 2 |
Bank of New York Mellon
New York
|
+$114K |
| 3 |
CCM
Cohen Capital Management
Corte Madera,
California
|
+$101K |
| 4 |
Morgan Stanley
New York
|
+$52.7K |
| 5 |
Goldman Sachs
New York
|
+$44.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$282K |
| 2 |
BlackRock
New York
|
-$248K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$194K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$123K |
| 5 |
State Street
Boston,
Massachusetts
|
-$121K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Two Sigma Advisers
New York
| – | -$64K | -381 | Closed |
|
27
SG Americas Securities
New York
| – | -$41K | -245 | Closed |
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$18K | -106 | Closed |
|
|
VF
29
Virtu Financial
New York
| – | -$13K | -79 | Closed |
|
|
SO
30
STRS Ohio
Columbus,
Ohio
| – | -$12K | -76 | Closed |
|
31
Charles Schwab
San Francisco,
California
| – | -$13K | -75 | Closed |
|
32
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| – | -$9K | -56 | Closed |
|
33
New York State Common Retirement Fund
Albany,
New York
| – | -$7K | -39 | Closed |
|
|
AIG
34
American International Group
New York
| – | -$4K | -23 | Closed |
|
35
JP Morgan Chase
New York
| – | -$1K | -9 | Closed |
|
36
Wells Fargo
San Francisco,
California
| – | -$618 | -4 | -67% |
|
ONCT Hedge Fund Activity: Q2 2019 in Review
24 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2019, worth a combined $1.93M — down 30% from $2.74M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ONCT and 3 opened new positions — a net loss of 11 holders — while 8 trimmed existing stakes and 9 added.
The largest buyer was Aureus Asset Management, opening a new position worth an estimated $542K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $282K sold.
- 24 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2019, down from 35 in Q1 2019.
- Funds reported $1.93M of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2019, down 30% quarter-over-quarter.
- 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2019 and 14 closed out, a net change of -11 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2019 was Aureus Asset Management, an estimated $542K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q2 2019 was Renaissance Technologies, an estimated $282K sold.
Based on aggregated 13F filings for Q2 2019.